Strategies
Better Science, Better Lives
Guided by our purpose, “Better Science, Better Lives,” PharmaEssentia aspires to become a world-class innovative biopharmaceutical company. We are committed to advancing innovative medicines with sustainability at the heart of our research and development.
Drawing on the framework of the Access to Medicine Index, we have established guiding principles for our access-to-medicine strategy, focusing on enhancing accessibility, affordability, and availability. These principles form a core part of our commitment to improving access to medicines for patients worldwide.
Our Goals and Vision
Our vision is to translate innovative science into meaningful healthcare solutions that create value for patients and address unmet medical needs.
Nearly two billion people worldwide still lack access to essential medicines. Through our core capabilities in innovative drug development, we have a unique opportunity to make a meaningful difference in people’s lives. By contributing to universal health coverage and health equity, in line with SDG 3.8, we strive to help ensure that people can access the medicines they need, wherever they are.
In 2025, we continued to expand potential indications through our global clinical trial programs while taking concrete actions to shorten the time it takes for underserved patients with rare diseases to gain access to needed medicines.
Leveraging Our Core Capabilities to Advance the SDGs
Our sustainability strategy integrates efforts across the pharmaceutical value chain, leveraging our core capabilities in innovative drug development to address material sustainability issues across the environmental, social, and governance dimensions. Through these efforts, we seek to create shared value for patients and contribute to SDG 3: Good Health and Well-being.
To address the medical needs of patients with rare diseases worldwide, we focus on key sustainability priorities, including:
-
Environmental Sustainability — SDGs 3, 12, 13 and 15
We published our first Biodiversity and No-Deforestation Commitment, reinforcing our efforts to protect terrestrial ecosystems.
-
Product Innovation — SDGs 9 and 17
-
Human Capital Management — SDGs 5 and 8
-
Patient Access and Affordability — SDGs 3, 9 and 17
-
Business Ethics — SDGs 3, 16 and 17
-
Product Quality and Safety — SDGs 3, 9 and 17
-
Patient Health and Engagement — SDGs 3, 9 and 17
Through these sustainability initiatives, we aim to generate positive and lasting impacts for society, patients, and the pharmaceutical industry, while advancing equitable access to innovative medicines and contributing to a healthier and more sustainable future.
Goals
Integrating Sustainability into Our Business Strategy
As a science-driven biopharmaceutical company, we place United Nations Sustainable Development Goal (SDG) 3: Good Health and Well-being at the heart of our mission and core capabilities.
Our sustainability approach is informed by internationally recognized frameworks and standards, including the Sustainability Accounting Standards Board (SASB) Biotechnology & Pharmaceuticals Industry Standard, the GRI Standards, the United Nations Global Compact, and the Access to Medicine Index. We are also actively preparing to align with Taiwan’s Financial Supervisory Commission (FSC) roadmap for the adoption of the IFRS Sustainability Disclosure Standards.
By integrating environmental, social, and governance (ESG) considerations into our business operations and corporate strategy, we seek to promote balanced economic, social, and environmental development. Through continuous innovation, we strive to build a sustainable company that earns the trust of patients and delivers meaningful improvements in health and well-being.
Advancing the SDGs Across Our Value Chain
In addition to placing SDG 3: Good Health and Well-being at the core of our sustainability strategy, we align material sustainability topics across the different stages of our value chain with a broad range of the United Nations Sustainable Development Goals.
Our ESG initiatives contribute to the following SDGs:
-
Environmental (E): SDGs 3, 12, 13, and 15 (Life on Land), newly incorporated in 2025
-
Social (S): SDGs 3, 4, 5, 8, 9, 10, 11, 13, 15, 16, and 17
-
Governance (G): SDGs 3, 16, and 17